



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

# INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.3381568>
Available online at: <http://www.iajps.com>

Research Article

## SEBELIPASE ALFA NEW THERAPY OF CHOICE FOR WOLMAN DISEASE

Soumya Mula<sup>1</sup>, Harinath Jolapuram<sup>2</sup>, Dhanunjay Valluru<sup>3</sup>.<sup>1</sup>Scientific writer, Global pharma Tek LLC , Hyderabad<sup>2</sup>Scientific writer, Global pharma Tek LLC , Hyderabad<sup>3</sup>Scientific writer, Global pharma Tek LLC , Hyderabad

Article Received: June 2019

Accepted: July 2019

Published: August 2019

**Abstract:**

*Lysosomal enzyme activity deficiency (LAL-D) is a rare disorder of cholesterol metabolism of cellular steroid alcohol and for the physiology of lipoprotein diseases. When deficient in lysosomal acid lipase (LAL), the enzyme results in deposited with steroid alcohol and triglycerides in a specific number of tissues. Future clinical results of adult and LAL patient medical care were assessed mainly using advantages of Sebelipase Alfa medical services that improve quality and life by examining several papillary diseases. Square measures were used to evaluate the clinical results of Sebelipase Alfa medicine. There is no cure, in particular, ongoing trails to enhance the sebelipase generation. Supportive management with lipid-modifying agents does not ameliorate disease progression. Hematopoietic stem cell transplantation as a curative measure in infantile disease has mixed success and is associated with inherent risks, complications and liver transplantation complexity by comparing the methods. Sebelipase was proved to be long term therapy for affected individuals. (Kanuma) is the human LAL protein recombinant and the first LAL-D treatment was enzyme replacement therapy. In infants with rapid progressive LAL-D adults and children with later-onset LAL-D, clinical studies were undertaken. There is no cure to particular disease but it can increase life expectancy of affected patient.*

**Key Words:** lysosomal acid lipase, cholesteryl esters, triglycerides, calcification, Kanuma

**Corresponding author:****Soumya Mula,**

Scientific writer.

Global pharma Tek, Hyderabad 500034, Telangana, India.

Email id: [soumya@globalpharmatek.com](mailto:soumya@globalpharmatek.com)

Phone Number: +919989849790.

QR code



Please cite this article in press as Soumya Mula., *Sebelipase Alfa New Therapy Of Choice For Wolman Disease.*, Indo Am. J. P. Sci, 2019; 06[08].

**INTRODUCTION:**

Wolman disease (WD) is an autosomal recessive storage disorder caused by very low (or absent) lysosomal acid lipase (LAL) activity (1). The deficiency of this enzyme leads to massive intracellular accumulation of cholesteryl esters and triglycerides. The WD represents the severe form of LAL deficiency in which patients present in early infancy with steatorrhea, chronic emesis, failure to thrive, and hepatosplenomegaly (2). Over the first year of life, people affected normally die without therapy. The fatty material, cholesterol ester, and triglycerides, in the body, is broken down by this enzyme. The absence of the LAL enzyme can lead to the accumulation of fatty matter in various body bodies such as the liver, spleen, intestines, blood vessel walls, and other significant bodies. An ultrasound test reveals that about half of the lysosomal acid lipase deficiency (LAL-D) babies have accumulated calcium calcified in their glands (3). The illness progresses in infants, with an enhanced accumulation of fat in the liver which leads to complications. The LAL-D complications, which eventually lead to life-threatening problems such as particularly low levels of blood-red circulatory cells (severe anemia), liver dysfunction.

Currently concentrating on Sebelipase Alfa (kanuma), a recombinant form of the enzyme LAL used to treat individuals with LAL-D, the best approach that improves the life expectancy of newborns, adults. Currently, Wolman disease has no cure or particular therapy. Death generally occurs at the age of six months. Sebelipase Alfa binds the glycan expressed on the protein to the cell surface receptors and is internalized in lysosomes subsequently. Sebelipase

Alfa catalyzes free cholesterol, glycerol and free fatty acids with the lysosomal hydrolysis of Cholesterol Esters and Triglycerides.

**METHODS:**

Reviewed various articles from different clinical phases I,II,III it was found as a solution for intravenous infusion. The literature search was conducted using a peer-reviewed search approach.

**RESULTS:**

By reviewing retrieving articles, Preclinical studies were done in a LAL-deficient rat model and showed 100% survival of treated *versus* untreated animals, as well as a significant improvement of hepatic lipid storage (4). Clinical trials in humans subsequently revealed good tolerability of Sebelipase Alfa and significant improvement of LAL-D related symptoms, as well as improved survival in infantile-onset LAL-D.

**Participant study:** Of nine people initiation of Sebelipase Alfa 1 mg/kg given weekly once as treatment, weight-for-age improvement in 3 out of 5 surviving growth failure patients and all 6 remaining weight improvement in patients after increases to 3 mg/kg weekly once showed proof of rapidly progressive LAL deficiency in patients during first 6-months of life. There was also a beneficial impact on the lipid profile of Sebelipase Alfa therapy. In 66 pediatric and adult patients, the safety and effectiveness of Kanuma have been evaluated further the findings have shown a beneficial safety profile and a statistically significant drop in liver transaminases (5).

**TABLE 1: REVIEWING VARIOUS CLINICAL TRAILS ARTICLES:**

TRAIL NAME	PHASES	OUTCOME OF RESULT
LAL-CL01	I	The safety profile of liver aminase
LAL-CL04	II	Efficacy of sebelipase alfa in patients with LAL deficiency
LAL-CL02	III	There was no clear association between the development of ADA (anti-drug antibodies) and hypersensitivity reactions
LAL-CL03	II/III	Rapidly progressive LAL deficiency in lipid parameters

**Advantages of enzymatic recombinant Sebelipase**

**Alfa:** Sebelipase Alfa is a recombinant human LAL made from *Gallus domesticus* hens in egg white. The mannose 6-phosphate residue is connected to the hepatocyte and macrophage lysosomes, where cholesterol esters and triglycerides can eventually be hydrolyzed (6). By reviewing other article clinical studies in people subsequently found that Sebelipase Alfa is well-tolerated and LAL-D related symptoms significantly enhanced, as well as childhood LAL-D survival, enhanced. The recombinant enzyme for the therapy of LAL-D in both children and adults has been endorsed. None of the patient's experience clinically concerning adverse events and no antibodies against infusion drugs could be detected. Mouse model of LAL-D infusion of recombinant human revealed histological improvement in organs which are several noted in Kuffer cells (7).

**Disadvantages of other methods:**

**Liver transplantation:** Severe patients with infancy/adult LAL-D, in which most of which were pediatric patients, have been shown to be suffering from a liver transplant. For these patients, long-term follow-up data is restricted, with multiple instances reporting good results between 10 months and 3 years after transplantation, one patient has had transplants rejection and congestive heart failure.

The literature has examined 18 instances of LAL-D post-liver transplantation. Eleven (61%) and six (33 %) of the patients died of multi-systemic LAL-D development (8) (9). These studies show that liver transplant may be essential but is not enough to avoid LAL-D associated liver insufficiency.

**Lipid-lowering medication:** High LDL-C (Low-density lipoprotein cholesterol) and low HDL-C (High-density lipoprotein cholesterol) are frequently tried to correct the HMG-CoA (Hydroxyl methyl glutaryl-coenzyme A) reductase inhibitors (statins) in patients with LAL-D in childhood/ adult. While dyslipidemia often improves, the therapeutic reaction is often not enough and high doses or combinations of statins are required. Despite its obvious lipid modifications, it remains uncertain whether statins improve or reduce premature atherosclerosis in these patients.

**Proper nutrition:** Despite dietary modifications such as low-fat formula and supplementation with medium-chain triglycerides it is insufficient to cope with malnutrition. Consultation with a nutrition team to limit malnutrition including the use of parenteral nutrition; corticosteroid and mineralocorticoid

replacement in the presence of adrenal insufficiency can be better (10).

**Hematopoietic stem cell transplantation:** The results were generally poor, with significant co-morbidities and 50% mortality. However, improvements must be introduced in the bone marrow transplant system since the previous morbid pathology increases toxicity and can stop the burial. Alternative changes must be examined to complete continuous burial without toxicity. Additional prospective therapies must be checked for Wolman disease patients, deaths after transplant were also reported: two out of four patients in one sequence of cases died of sinusoidal obstruction syndrome (11).

**DISCUSSION:**

Stem cell/Bone marrow transplantation for LAL-D is potentially curative, as normal LAL activity will be derived from donor cells (11). Stem cell/one marrow transplantation for LAL-D is potentially curative as normal LAL activity will be derived from donor cells, but outcomes of Hematopoietic stem cell transplantation (HSCT) have been mixed (12). Successful cases of bone marrow and umbilical cord blood transplantation have been documented up to 4 to 11-years post-transplantation, with normalization of LAL, improved lipid parameters, resolution of symptoms, regression of Hepatosplenomegaly, and histological improvement in the liver. Moreover, it importantly, statins have shown no benefit in modifying the progression of liver disease. The magnetic resonance image (MRI) scan of an adult patient diagnosed with a cholesterol ester storage disability for Hepatosplenomegaly and liver steatosis. Although some reports have noted improved liver histology such as reduced hepatocyte vacuolation, no comment was made on the progression or otherwise of liver fibrosis in liver transplantation, (13). One case of transplantation in an adult female with LAL-D reported satisfactory graft function 2 years post-procedure and improved lipid profile, although peripheral LAL levels remained low. Evidence for long-term mortality and morbidity post-transplantation are currently limited (14).

**CONCLUSION:**

The Above review concluded that Sebelipase Alfa is efficient, safer with the reduction of Hepatic, Dyslipidemia, Cardiovascular disease in infantile and adults, on early diagnosis. Overall, Sebelipase Alfa has a favorable safety profile and promises to be a good long-term treatment option for patients with LAL-D, with a significant reduction of disease burden and increased life expectancy. Currently, the studies are going on further Sebelipase Alfa is the first of its type

in LAL-D for Enzyme replacement therapy. Current data show significant impacts on the survival of children with rapidly progressive disease and significant improvements in biochemical parameters of the older LAL-D group.

# REFERENCE:

1. Dominik Soll, Dominik Spira, Tim Hollstein et.al. Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report, molecular genetics, and metabolism reports, 2019.
2. M.Pascual, IsaacMarin-ValenciaJuan. Wolman Disease, fifth edition, s.l. : Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, 2015.
3. Doss, S.A.Syed Haneef.George Priya. s.l. , Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.: Advances in Protein Chemistry and Structural Biology, 2016, Vol. 102.
4. Erwin, Angelika L. s.l. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. : Therapy Adv Gastroenterol., 2017, Vol. 10(7).
5. Fouchier, Sigrid and Defesche, Joep. 0957-9672, s.l., Lysosomal acid lipase A and the hypercholesterolaemic phenotype. : Current Opinion in Lipidology., 2013, Vol. 24(4).
6. Kim Su, Emma Donaldson, Reena Sharma et.al. s.l. , Novel treatment options for lysosomal acid lipase deficiency: a critical appraisal of sebelipase alfa.: Appl Clin Genet, 2016, Vol. 9.
7. ChristinaLeopoldaMadalinaDuta-MareaVinaySachdev. s.l. et.al, Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. : Biochim Biophys Acta Mol Cell Biol Lipids., 2019, Vol. 1864(4).
8. Fouchier SW, Defesche JC. 4, s.l. , Lysosomal acid lipase A and the hypercholesterolaemic phenotype.: current opinion in lipidology, 2013, Vol. 24.
9. Bernstein DL, Lobritto S, Iuga A et.al. 1, s.l. , Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients.: molecular genetics and metabolism, 2018, Vol. 124.
10. Hoffman EP, Barr ML, Murray MF et.al. Lysosomal Acid Lipase Deficiency. [pub reader] s.l. : Lysosomal Acid Lipase Deficiency., GeneReviews, 2016.
11. Su K, Donaldson E, Sharma R. s.l. , Novel treatment options for lysosomal acid lipase deficiency: a critical appraisal of sebelipase alfa.: The application of clinical Genetics, 2016, Vol. 9.
12. Jyonouchi H, Cyong JC, Shen FW et.al. 1, s.l. , Alteration of murine serum lipase activity after allogeneic bone marrow transplantation.: Clin Immunol Immunopathol, 1982, Vol. 22.
13. Bernstein DL, Hulkova H, Bialer MG et.al. 6, s.l., Cholesteryl ester storage disease: a review of the findings in 135 reported patients with an underdiagnosed disease. : Journal of hepatology, 2013, Vol. 58.
14. Tolar J, Petryk A, Khan K, et al. 1, s.l. , Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. : Bone Marrow Transplant. , 2009, Vol. 43.